Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19533849 | 0.81 | CYP1A2 (0.42) | ALDH1A1CA12CA9POLBCASP3 | |
| SCHEMBL20954062 | 0.79 | POLB (0.46) | ALDH1A1CA12CA9POLBCASP3 | |
| SCHEMBL238005 | 0.77 | POLB (0.44) | ALDH1A1CA12CA9POLBCASP3 | |
| SCHEMBL30996374 | 0.77 | POLB (0.44) | ALDH1A1CA12CA9POLBCASP3 | |
| SCHEMBL23604158 | 0.75 | POLB (0.43) | ALDH1A1CA12CA9POLBCASP3 | |
| SCHEMBL1553885 | 0.75 | CASP3 (0.46) | ALDH1A1CA12CA9POLBCASP3 | |
| SCHEMBL8119562 | 0.75 | CASP3 (0.46) | ALDH1A1CA12CA9POLBCASP3 | |
| SCHEMBL7223794 | 0.75 | EHMT2 (0.50) | ALDH1A1CA12CA9POLBCASP3 | |
| SCHEMBL35297 | 0.75 | ALDH1A1 (0.48) | ALDH1A1CA12CA9POLBCASP3 | |
| SCHEMBL5348888 | 0.75 | POLB (0.43) | ALDH1A1CA12CA9POLBCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | claimed |
| EP-1004593-A2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | claimed |
| US-5618704-A | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling | ISIS PHARMACUETICALS, INC. (US) | 1997-04-08 | — | — | US | claimed |
| US-5610289-A | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 1997-03-11 | — | — | US | claimed |
| EP-0586570-A4 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 1996-01-24 | — | — | EP | claimed |
| EP-0586570-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-16 | — | — | EP | claimed |
| WO-1992020822-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | claimed |
| US-6900301-B2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-20020183502-A1 | Backbone-modified oligonucleotide analogs and methods for using same | MESMAEKER ALAIN DE (CH) | 2002-12-05 | — | — | US | disclosed |
| US-6214551-B1 | CONTACTING TEST SOLUTION CONTAINING NUCLEIC ACID WITH COMPOUND CONTAINING NUCLEOSIDE SEQUENCE WHEREIN NUCLEOSIDES ARE COVALENTLY BOUND THROUGH LINKING GROUP HAVING ADJACENT NITROGEN ATOMS FOR ASSAYING SEQUENCE-SPECIFIC NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. | 2001-04-10 | — | — | US | disclosed |
| US-6087482-A | INTER-SUGAR LINKAGES ARE FOUR ATOM LINKING GROUPS; FOR IMPROVED NUCLEASE RESISTANCE AND CELLULAR UPTAKE; FOR DIAGNOSIS AND ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-1004593-A2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1994022894-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND PREPARATION THEREOF THROUGH RADICAL COUPLING | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022883-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDES AND THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022886-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0586520-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0586570-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020822-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020823-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183502-A1 | Backbone-modified oligonucleotide analogs and methods for using same | RNGTT, RNASE1, ADAR | ALDH1A1 4078/4885CA12 2184/4885CA9 3726/4885 |
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | RNASE1, RNGTT, NSUN2 | ALDH1A1 3913/4885CA12 2256/4885CA9 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.